Sugi Predict

Sugi Predict / Compounds / SCHEMBL1615896

SCHEMBL1615896

SCHEMBL1615896

COC(=O)c1ccc(C(=O)Nc2ccc3c(c2)C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP26A1 O43174 6/20 0.76
▸ RARA P10276 6/20 0.76
▸ RARB P10826 5/20 0.76
▸ RARG P13631 5/20 0.76
▸ CYP3A4 P08684 5/20 0.76
▸ KMT2A Q03164 3/20 0.76
▸ MEN1 O00255 2/20 0.76
▸ PGR P06401 1/20 0.76
▸ ADORA3 P0DMS8 1/20 0.76
▸ TBXA2R P21731 1/20 0.76
▸ BLVRB P30043 1/20 0.76
▸ CYP26B1 Q9NR63 2/20 0.67
▸ ALDH1A1 P00352 1/20 0.64
▸ CYP1A2 P05177 1/20 0.64
▸ CYP2C9 P11712 1/20 0.64
▸ TSHR P16473 1/20 0.64
▸ MAPK1 P28482 1/20 0.64
▸ CYP2C19 P33261 1/20 0.64
▸ CTDSP1 Q9GZU7 1/20 0.55
▸ RAB9A P51151 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1615390 0.92 RARA (0.76) CYP26A1RARARARBRARGCYP3A4
SCHEMBL1615594 0.89 CYP26A1 (0.60) CYP26A1RARARARBRARGCYP3A4
SCHEMBL22001408 0.87 RARA (0.69) CYP26A1RARARARBRARGCYP3A4
SCHEMBL7622775 0.87 CYP26A1 (0.57) CYP26A1RARARARBRARGCYP3A4
SCHEMBL17049087 0.86 CYP3A4 (0.61) CYP26A1RARARARBRARGCYP3A4
Tamibarotene SCHEMBL36207 0.86 RARB (1.00) CYP26A1RARARARBRARGCYP3A4
SCHEMBL19560600 0.86 RARA (0.80) CYP26A1RARARARBRARGCYP3A4
Tamibarotene SCHEMBL29373818 0.86 RARB (1.00) CYP26A1RARARARBRARGCYP3A4
SCHEMBL1615110 0.86 RARA (0.80) CYP26A1RARARARBRARGCYP3A4
SCHEMBL13999715 0.86 CYP26A1 (0.80) CYP26A1RARARARBRARGCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210308026-A1 TOPICAL COMPOSITIONS FOR REDUCING THE EFFECTS OF AGING SAMSON PHARMA, LLC (US) 2021-10-07 — — US disclosed
US-11039995-B2 Topical compositions for reducing the effects of aging SAMSON PHARMA, LLC (US) 2021-06-22 — — US disclosed
US-20200330415-A1 DRUG FOR RETINAL DEGENERATIVE DISEASE ASSOCIATED WITH PHOTORECEPTOR DEGENERATION DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-10-22 — — US disclosed
US-10265254-B2 — — 2019-04-23 — — US disclosed
US-20160000674-A1 TOPICAL COMPOSITIONS FOR REDUCING THE EFFECTS OF AGING AVISENNA COSMETICS, LLC (US) 2016-01-07 — — US disclosed
US-8633335-B2 Retinoid prodrug compound Research Founation Itsuu Laboratory (JP) 2014-01-21 — — US disclosed
US-8633335-B2 Retinoid prodrug compound Research Founation Itsuu Laboratory (JP) 2014-01-21 — — US disclosed
US-7923579-B2 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2011-04-12 — — US disclosed
US-7923579-B2 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2011-04-12 — — US disclosed
US-7923579-B2 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2011-04-12 — — US disclosed
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2007-06-07 — — US disclosed
EP-1692097-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS Exonhit Therapeutics SA (FR) 2006-08-23 — — EP disclosed
WO-2005058803-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2005-06-30 — — WO disclosed
WO-2005058803-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2005-06-30 — — WO disclosed
EP-1541549-A1 Tricyclic hydroxamate and benzaminde derivatives, compositions and methods Exonhit Therapeutics S.A. (FR) 2005-06-15 — — EP disclosed
US-5869067-A TREATING DERMATOLOGICAL DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1999-02-09 — — US disclosed
US-5753239-A Bi-aromatic compounds and pharmaceutical and cosmetic compositions CENTRE INTERNATIONAL DE RECHERCHES DEMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1998-05-19 — — US disclosed
EP-0478787-B1 NOVEL PROCESS FOR PRODUCING BENZOIC ACID DERIVATIVE SHIONOGI & CO (JP) 1994-12-21 — — EP disclosed
US-5214202-A Retinoid activity SHIONOGI & CO., LTD. (JP) 1993-05-25 — — US disclosed
EP-0478787-A1 NOVEL PROCESS FOR PRODUCING BENZOIC ACID DERIVATIVE SHIONOGI & CO., LTD. (JP) 1992-04-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods HDAC5, HDAC1, HDAC2 CYP26A1 1813/4885RARA 1012/4885RARB 998/4885
US-20200330415-A1 DRUG FOR RETINAL DEGENERATIVE DISEASE ASSOCIATED WITH PHOTORECEPTOR DEGENERATION RARB, RARA, RARG CYP26A1 1848/4885RARA 2/4885RARB 1/4885
US-20160000674-A1 TOPICAL COMPOSITIONS FOR REDUCING THE EFFECTS OF AGING ARG2, ARG1, MTPN CYP26A1 3288/4885RARA 342/4885RARB 255/4885
US-10265254-B2 — ARG2, MTPN, LDHB CYP26A1 3330/4885RARA 720/4885RARB 453/4885
US-11039995-B2 Topical compositions for reducing the effects of aging ARG2, ARG1, MTPN CYP26A1 3288/4885RARA 342/4885RARB 255/4885
US-20210308026-A1 TOPICAL COMPOSITIONS FOR REDUCING THE EFFECTS OF AGING ARG2, ARG1, MTPN CYP26A1 3288/4885RARA 342/4885RARB 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.